Funding propels HoloMD’s clinician-led AI platform designed to expand access and improve psychiatric outcomes.

HoloMD, the AI-powered Remote Therapeutic Monitoring (RTM) platform for psychiatry, has completed a $1.6 million first close of its $3 million seed round. The company will host a virtual investor presentation on Tuesday, November 11, at 12:00 p.m. ET, to share progress and next-stage growth plans. Interested investors may RSVP to Dominic Fabrizio at Dominic@HoloMD.ai.

Expanding Access and Scaling Dr. Holo

The new capital will accelerate the development and expansion of Dr. Holo™, The AI-Powered Mental Health Superhero™, a human-supervised AI companion that supports psychiatrists and their patients between visits through daily engagement, evidence-based interactions, and actionable clinical insights. Built on 40 years of award-winning psychiatric expertise, the platform helps providers deliver high-quality care between sessions- improving outcomes, reducing burnout, and creating new revenue streams through Remote Therapeutic Monitoring (RTM) reimbursement.

In just 15 months, HoloMD has completed Phase 1 of its platform rollout - moving from concept to live revenue and proving its reimbursement model in the field. Early deployments have demonstrated strong patient engagement, positive clinician feedback, and validated RTM billing across multiple commercial payers. With this foundation in place, HoloMD is preparing to expand into additional practices and markets as it advances to the next phase of growth.

AI with a Human Touch

Dr. Holo engages patients through daily check-ins and micro-interventions, then translates emotion, context, and behavior into concise, visit-ready insights for providers. Each interaction is reviewed by licensed clinicians to ensure safety, empathy, and accuracy - balancing scalable automation with human supervision. The platform structures these interactions for RTM CPT compliance, turning previously unpaid work into work that is eligible for reimbursement.

“Built by psychiatrists for psychiatrists and PMHNPs, our mission is to extend healing beyond the clinic walls,” said Bruce A. Kehr, MD, Founder & CEO of HoloMD. “Dr. Holo engages patients every day, surfaces what’s going well and what isn’t, and equips clinicians with actionable insights to improve diagnosis and treatment, while enabling care between visits that is eligible for reimbursement.”

“HoloMD sits at the intersection of better outcomes and better economics,” said Jim Pearson, HoloMD’s Executive Chairman. “By aligning eligible RTM reimbursement with continuous patient support, we have created a sustainable model that is designed to help clinicians improve outcomes while scaling care sustainably.”

Investment Highlights

1. Proven leadership: Executive Chairman Jim Pearson—three prior healthcare exits totaling $450 M (Stryker, Hologic).
2. Clinically founded: 40 years of award-winning psychiatric expertise from Dr. Bruce Kehr and Potomac Psychiatry.
3. Reimbursement-backed: Validated RTM workflows reimbursed by Medicare & commercial payers.
4. Human-supervised AI: Scalable automation with clinician oversight—“science with soul.”
5. IP momentum: Patent-pending platform with expanding national pipeline.

About HoloMD

HoloMD has brought to market a patent-pending AI-powered psychiatry platform that augments clinicians with continuous, human-supervised patient engagement - and RTM-aligned workflows - to provide mission-critical information designed to improve outcomes and reduce costs. Founded in July 2024, the company is fully HIPAA- and HITECH-compliant, supports Medicare RTM billing, and currently has seven provisional and one utility patent pending and three trademarks pending. Learn more at HoloMD.ai.

Investor Presentation - November 11, 2025 (Virtual)

Time: 12:00 p.m. ET (45 minutes – Q&A Individually scheduled)

RSVP: Dominic@HoloMD.ai

This release contains forward-looking statements subject to risks and uncertainties. It is provided solely for informational purposes and does not constitute an offer to sell securities. Prospective investors should rely on official offering materials and conduct their own due diligence.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104098142/en/